secwatch.observer — SEC 8-K summary
======================================

Issuer:     ULTRALIFE CORP (ULBI)
CIK:        0000875657
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001437749-24-013119
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultralife Q1 sales up 31.4% to $41.9M; GAAP EPS $0.18 vs -$0.02 YoY
-------------------------------------------------------------------

- Revenue $41.9M (+31.4% YoY); government/defense sales +83.4%, medical battery sales +54.7%.
- GAAP EPS $0.18 vs net loss $0.02; adjusted EPS $0.21. Operating income $4.1M vs breakeven.
- Gross margin 27.4% vs 23.3% YoY; Battery & Energy margin 25.7% vs 22.9%.
- Backlog $97.4M; adjusted EBITDA $5.2M (12.5% of sales) vs $1.2M (3.6%).
- CEO cites gross margin initiatives and core product demand; expects profitable growth and cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875657/000143774924013119/0001437749-24-013119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875657/000143774924013119/ulbi20240424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-013119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer